# Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)

> **NCT06602011** · — · RECRUITING · sponsor: **Fujian Provincial Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** TACE, Lenvatinib, combined with Tislelizumab group

## Key facts

- **NCT ID:** NCT06602011
- **Lead sponsor:** Fujian Provincial Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06602011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06602011, "Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06602011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*